Therapeutic options for early-stage ER/PR+ breast cancer include adjuvant endocrine therapy, and for clinical or genomic high-risk ER/PR+, neoadjuvant or adjuvant chemotherapy, as well as adjuvant cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). This evidence concerns the gene PGR and breast carcinoma.